Trial · NCT07900399
Effects of the 11 for Health Program on Physical Fitness and Health-Related Outcomes in Schoolchildren
NCT07900399, Not applicable, Not yet recruiting, Namik Kemal University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of the 11 for Health Program on Physical Fitness and Health-Related Outcomes in Schoolchildren. Trials, record NCT07900399. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900399
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of the 11 for Health Program on Physical Fitness and Health-Related Outcomes in Schoolchildren
- NCT number
- NCT07900399
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Namik Kemal University
- Conditions
- Physical Fitness, Health, Body Composition
- Interventions
- 11 for Health Program
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Countermovement Jump Height | Baseline (Week 1) and post-intervention assessment (Week 13, approximately 12 weeks after baseline) | Countermovement jump (CMJ) height will be measured using VALD ForceDecks force platforms. Jump height will be calculated using the impulse-momentum method and reported in centimeters (cm). Higher values indicate greater jump height. |
| Primary | Change in Single-Leg Balance: Center of Pressure Mean Velocity | Baseline (Week 1) and post-intervention assessment (Week 13, approximately 12 weeks after baseline) | Single-leg balance will be assessed using VALD ForceDecks force platforms. Center of pressure (CoP) mean velocity will be recorded in millimeters per second (mm/s) during a 30-second single-leg standing test. Lower values indicate less postural sway. |
| Primary | Change in T-Test Completion Time | Baseline (Week 1) and post-intervention assessment (Week 13, approximately 12 weeks after baseline) | Change-of-direction performance will be assessed using the T-Test. Participants will complete a standardized course involving forward, lateral, and backward movements. Completion time will be recorded in seconds using timing gates. Lower values indicate faster performance. |
| Primary | Change in Body Fat Percentage | Baseline (Week 1) and post-intervention assessment (Week 13, approximately 12 weeks after baseline) | Body fat percentage will be assessed using a bioelectrical impedance analysis (BIA) device. Results will be expressed as a percentage of total body mass. |
| Secondary | Change in Sit-and-Reach Test Performance | Baseline (Week 1) and post-intervention assessment (Week 13, approximately 12 weeks after baseline) | Flexibility will be assessed using the sit-and-reach test. Reach distance will be recorded in centimeters (cm). |
| Secondary | Change in Systolic Blood Pressure | Baseline (Week 1) and post-intervention assessment (Week 13, approximately 12 weeks after baseline) | Systolic blood pressure will be measured using an automated blood pressure monitor and reported in millimeters of mercury (mmHg). |
| Secondary | Change in Diastolic Blood Pressure | Baseline (Week 1) and post-intervention assessment (Week 13, approximately 12 weeks after baseline) | Diastolic blood pressure will be measured using an automated blood pressure monitor and reported in millimeters of mercury (mmHg). |
| Secondary | Change in Resting Heart Rate | Baseline (Week 1) and post-intervention assessment (Week 13, approximately 12 weeks after baseline) | Resting heart rate will be measured using an automated blood pressure monitor and reported in beats per minute (bpm). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900399
GET https://conductscience.org/api/trials/v1/NCT07900399/registered